Scholarlink

<p>The aim of this study was to determine serum I-309 levels in primary Sjögren’s syndrome (pSS) patients, as well as the association with disease phenotype, systemic activity, and T helper cell-related cytokines.&#xa0;A total of 58 pSS patients and 30 healthy controls (HC) were enrolled in this study. The concentrations of serum I-309, interleukin-4 (IL-4), IL-6, IL-9, IL-13, IL-17, IL-22, IL-23, tumor-necrosis factor-α (TNF-α), interferon-γ (IFN-γ), IFN-α, and IFN-β were measured with multiplex immunoassay. The relationships between I-309 and various clinical and laboratory variables were analyzed.&#xa0;The serum concentrations of I-309 were significantly increased (median, IQR, 14.24, 10.99-–20.35, pg/ml) in pSS patients compared with HC (median, IQR, 8.27, 6.74-–9.62, pg/ml) (P &lt; 0.001).&#xa0;Serum I-309 is increased in pSS, and may be associated with systemic inflammation, Th1-, Th17,- and Th9 cells, type</p><p><Table Float="No" ID="Taba"> <tgroup cols="1"> <colspec align="left" colname="c1" colnum="1" /> <tbody> <row> <entry align="left" colname="c1"> <p><b>Key Points</b></p> </entry> </row> <row> <entry align="left" colname="c1"> <p>• <i>Serum I-309 levels are increased in pSS patients.</i></p> <p>• <i>Increased I-309 may be associated with systemic rather than local manifestations in pSS.</i></p> <p>• <i>Increased I-309 may be associated with Th1, Th17 and Th9 other than Th2 in pSS.</i></p> <p>• <i>There may be close relationships between I-309 and type land type II IFNs in pSS.</i></p> </entry> </row> </tbody> </tgroup> </Table></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of increased serum I-309 with phenotypes, disease activity, and cytokine pattern in primary Sjögren’s syndrome

  • 期刊论文

  • 发表日期：

    2025年1月23日

查看全文
  • Yan Liang,
  • Zhiyu Zhang,
  • Jie Li,
  • Zaixing Yang

摘要

The aim of this study was to determine serum I-309 levels in primary Sjögren’s syndrome (pSS) patients, as well as the association with disease phenotype, systemic activity, and T helper cell-related cytokines. A total of 58 pSS patients and 30 healthy controls (HC) were enrolled in this study. The concentrations of serum I-309, interleukin-4 (IL-4), IL-6, IL-9, IL-13, IL-17, IL-22, IL-23, tumor-necrosis factor-α (TNF-α), interferon-γ (IFN-γ), IFN-α, and IFN-β were measured with multiplex immunoassay. The relationships between I-309 and various clinical and laboratory variables were analyzed. The serum concentrations of I-309 were significantly increased (median, IQR, 14.24, 10.99-–20.35, pg/ml) in pSS patients compared with HC (median, IQR, 8.27, 6.74-–9.62, pg/ml) (P < 0.001). Serum I-309 is increased in pSS, and may be associated with systemic inflammation, Th1-, Th17,- and Th9 cells, type

Key Points

• Serum I-309 levels are increased in pSS patients.

• Increased I-309 may be associated with systemic rather than local manifestations in pSS.

• Increased I-309 may be associated with Th1, Th17 and Th9 other than Th2 in pSS.

• There may be close relationships between I-309 and type land type II IFNs in pSS.